Yin Li, Bian Xiu-Hua, Wang Xue, Chen Meng, Wu Jing, Xu Jian-Hua, Qian Pu-Dong, Guo Wen-Jie, Jiang Xue-Song, Zhu Huan-Feng, Gu Jia-Jia, Wu Jian-Feng, Zhang Ye-wei, He Xia
Department of Radiation Oncology, Nanjing Medical University Affiliated Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P. R. China.
Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, P. R. China.
PLoS One. 2015 Sep 14;10(9):e0137383. doi: 10.1371/journal.pone.0137383. eCollection 2015.
N-stage is related to distant metastasis in nasopharyngeal carcinoma (NPC) patients. The purpose of this study was to evaluate the efficacy and toxicity of different nedaplatin-based chemotherapy regimens in advanced N2-3 stage NPC patients treated with intensity modulated radiation therapy (IMRT).
Between April 2005 and December 2009, a total of 128 patients with N2-3 advanced NPC were retrospectively analyzed. Patients were treated with IMRT concurrent with 2 cycles of chemotherapy consisting of either nedaplatin plus paclitaxel (NP group, n = 67) or nedaplatin plus fluorouracil and paclitaxel (NFP group, n = 61). Two to four cycles of adjuvant chemotherapy were then administered every 21 days following concurrent chemoradiotherapy.
With a median follow-up of 60 months, the 5-year overall survival (OS), progression-free survival (PFS), local-regional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) for all patients were 81.4%, 71.5%, 87.8% and 82.0%, respectively. No significant difference in PFS (66.6% vs. 76.7%, P = 0.212) and LRRFS rates (89.0% vs. 86.3%, P = 0.664) was observed between the NP and NFP groups. The 5-year OS (75.4% vs. 88.5%, P = 0.046) and DMFS (75.1% vs. 89.0%, P = 0.042) rate were superior in the NFP group compared with the NP group. The NFP group had a higher incidence of grade 3-4 acute toxicities including bone marrow suppression (leukopenia: χ2 = 3.935, P = 0.047; anemia: χ2 = 9.760, P = 0.002; thrombocytopenia: χ2 = 8.821, P = 0.003), and both liver and renal dysfunction (χ2 = 5.206, P = 0.023) compared with the NP group. Late toxicities were moderate and no difference was observed between the two groups.
IMRT concurrent with nedaplatin-based chemotherapy is an advocated regimen for patients with advanced N2-3 stage NPC. Patients with advanced N2-3 stage may be better candidates for the NFP regimen although this regimen was associated with a high acute toxicity rate.
N分期与鼻咽癌(NPC)患者的远处转移相关。本研究旨在评估不同的奈达铂为基础的化疗方案在接受调强放射治疗(IMRT)的晚期N2-3期NPC患者中的疗效和毒性。
回顾性分析2005年4月至2009年12月期间共128例N2-3期晚期NPC患者。患者接受IMRT同步2周期化疗,化疗方案为奈达铂加紫杉醇(NP组,n = 67)或奈达铂加氟尿嘧啶和紫杉醇(NFP组,n = 61)。同步放化疗后每21天给予2至4周期辅助化疗。
中位随访60个月,所有患者的5年总生存(OS)率、无进展生存(PFS)率、局部区域无复发生存(LRRFS)率和远处转移无复发生存(DMFS)率分别为81.4%、71.5%、87.8%和82.0%。NP组和NFP组之间在PFS率(66.6%对76.7%,P = 0.212)和LRRFS率(89.0%对86.3%,P = 0.664)方面未观察到显著差异。与NP组相比,NFP组的5年OS率(75.4%对88.5%,P = 0.046)和DMFS率(75.1%对89.0%,P = 0.042)更高。NFP组3-4级急性毒性的发生率更高,包括骨髓抑制(白细胞减少:χ2 = 3.935,P = 0.047;贫血:χ2 = 9.760,P = 0.002;血小板减少:χ2 = 8.821,P = 0.003)以及肝肾功能障碍(χ2 = 5.206,P = 0.023)。晚期毒性为中度,两组之间未观察到差异。
IMRT同步奈达铂为基础的化疗是晚期N2-级NPC患者的推荐方案。晚期N2-3期患者可能更适合NFP方案,尽管该方案急性毒性率较高。